Soft occlusal splint therapy in the management of myofascial pain dysfunction syndrome: a follow-up study.
OBJECTIVE
Myofascial Pain Dysfunction Syndrome (MPDS) has been recognized as the most common, nontooth-related chronic orofacial pain condition that confronts dentists. A variety of therapies has been described in literature for its management. The present study is a prospective study carried out to evaluate the efficacy of occlusal splint therapy and compare it with pharmacotherapy (using analgesics and muscle relaxants) in the management of Myofascial Pain Dysfunction Syndrome.


METHODS
Forty patients in the age range of 17-55 years were included in the study and randomly assigned to one of two equally sized groups, A and B. Group A patients received a combination of muscle relaxants and analgesics while Group B patients received soft occlusal splint therapy. All the patients were evaluated for GPI, VAS, maximum comfortable mouth opening, TMJ clicking and tenderness during rest and movement as well as for the number of tender muscles at the time of diagnosis, after the 1 st week of initiation of therapy and every month for three months of follow-up.


RESULTS
There was a progressive decrease in GPI scores, number of tender muscles, TMJ clicking and tenderness with various jaw movements and significant improvement in mouth opening in patients on occlusal splint therapy during the follow-up period as compared to the pharmacotherapy group.


CONCLUSIONS
Occlusal splint therapy has better long-term results in reducing the symptoms of MPDS. It has better patient compliance, fewer side effects, and is more cost-effective than pharmacotherapy; hence, it can be chosen for the treatment of patients with MPDS.
Naikmasur
Venkatesh
V
Department of Oral Medicine and Radiology, SDM College of Dental Sciences, Sattur, Dharwad - 580 009, Karnataka, India. drvnmasur@gmail.com
Bhargava
Puneet
P
Guttal
Kruthika
K
Burde
Krishna
K
D000082:Acetaminophen / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use; D002753:Chlorzoxazone / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007052:Ibuprofen / Q000627:therapeutic use; D008297:Male; D008410:Masticatory Muscles / Q000503:physiopathology; D008875:Middle Aged; D009125:Muscle Relaxants, Central / Q000627:therapeutic use; D009334:Neck Muscles / Q000503:physiopathology; D017090:Occlusal Splints; D016382:Orthodontic Appliance Design; D010147:Pain Measurement; D011446:Prospective Studies; D016059:Range of Motion, Articular / Q000502:physiology; D013016:Sound; D013499:Surface Properties; D013706:Temporomandibular Joint Dysfunction Syndrome / Q000188:drug therapy / Q000628:therapy*; D016896:Treatment Outcome
D018712:Analgesics, Non-Narcotic; D009125:Muscle Relaxants, Central; D000082:Acetaminophen; D002753:Chlorzoxazone; D007052:Ibuprofen